BNP Paribas purchased a new position in Synopsys, Inc. (NASDAQ:SNPS – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 70,658 shares of the semiconductor company’s stock, valued at approximately $29,981,000.
A number of other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Synopsys during the second quarter worth about $7,228,099,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Synopsys in the second quarter valued at approximately $747,400,000. Bank of New York Mellon Corp bought a new stake in shares of Synopsys in the second quarter valued at approximately $692,074,000. Bank of America Corp DE bought a new stake in shares of Synopsys during the 2nd quarter worth approximately $539,986,000. Finally, Legal & General Group Plc bought a new position in Synopsys in the 2nd quarter valued at approximately $491,923,000. 85.47% of the stock is owned by institutional investors and hedge funds.
Synopsys Price Performance
Shares of NASDAQ:SNPS opened at $396.55 on Friday. The company has a market capitalization of $76.00 billion, a PE ratio of 70.06, a PEG ratio of 1.26 and a beta of 1.18. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.34 and a quick ratio of 1.24. The business has a fifty day moving average price of $448.46 and a 200-day moving average price of $440.14. Synopsys, Inc. has a 1-year low of $362.55 and a 1-year high of $539.48.
Synopsys announced that its Board of Directors has approved a stock repurchase plan on Monday, October 5th that allows the company to buy back $1 billion in shares. This repurchase authorization allows the semiconductor company to reacquire up to 1.1% of its shares through open market purchases. Share repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
Insider Buying and Selling at Synopsys
In related news, insider Aart de Geus sold 24,641 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $419.44, for a total transaction of $10,335,421.04. Following the completion of the sale, the insider directly owned 120,443 shares in the company, valued at $50,518,611.92. This represents a 16.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sudhindra Kankanwadi sold 9,170 shares of the business’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $500.00, for a total value of $4,585,000.00. Following the sale, the chief financial officer owned 22,717 shares in the company, valued at $11,358,500. The trade was a 28.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 117,163 shares of company stock valued at $51,366,457. Corporate insiders own 0.56% of the company’s stock.
Top Synopsys Stories
Investors following SNPS have been watching these stories:
- Positive Sentiment: Synopsys-backed Ansys is supporting an integration between Instem’s toxicology tools and its simulation platform, extending the company’s reach into packaging safety and materials-risk workflows. This could broaden use of its simulation ecosystem, though the financial impact is not specified. Synopsys broadens platform reach
- Neutral Sentiment: Synopsys is described as having stronger forward growth and a lower forward valuation multiple than Cadence, but Cadence is credited with a stronger balance sheet and returns on capital. Synopsys vs. Cadence
- Negative Sentiment: A valuation analysis argues SNPS may be about 17% overvalued despite improving guidance and business performance, raising questions about whether future cash generation justifies the share price. Synopsys may be overvalued
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the stock. HSBC lowered shares of Synopsys from a “buy” rating to a “reduce” rating in a report on Friday, September 25th. Barclays began coverage on shares of Synopsys in a report on Thursday. They set an “overweight” rating and a $640.00 target price on the stock. Deutsche Bank restated a “buy” rating and set a $640.00 target price (up from $590.00) on shares of Synopsys in a research report on Thursday, October 1st. Morgan Stanley upped their target price on Synopsys from $500.00 to $574.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 20th. Finally, BNP Paribas Exane raised their target price on Synopsys from $420.00 to $475.00 and gave the stock a “neutral” rating in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $577.71.
Check Out Our Latest Report on SNPS
Synopsys Company Profile
Synopsys, Inc. develops software, semiconductor intellectual property (IP) and services used to design and verify electronic systems. Its electronic design automation (EDA) tools help customers create, simulate, test and validate chips and other complex electronic products, while its IP portfolio provides reusable building blocks for semiconductor designs. The company also offers software security and quality tools that help developers identify vulnerabilities and assess applications throughout the software development process.
See Also
- Five stocks we like better than Synopsys
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS – Free Report).
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
